Arcadia Biosciences (Arcadia Biosciences) Debt-to-Revenue : 0.22 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Arcadia Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Arcadia Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.85 Mil. Arcadia Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.16 Mil. Arcadia Biosciences's annualized Revenue for the quarter that ended in Dec. 2023 was $4.68 Mil. Arcadia Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.22.

Arcadia Biosciences Debt-to-Revenue Historical Data

The historical data trend for Arcadia Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcadia Biosciences Debt-to-Revenue Chart

Arcadia Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

1.92

1.16

0.49

0.27

0.19

Arcadia Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.68	0.29	0.27	0.20	0.22

Competitive Comparison of Arcadia Biosciences's Debt-to-Revenue

For the Packaged Foods subindustry, Arcadia Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcadia Biosciences's Debt-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Arcadia Biosciences's Debt-to-Revenue falls into.

Arcadia Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Arcadia Biosciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.852	+	0.155)	/	5.33
	=	0.19

Arcadia Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.852	+	0.155)	/	4.68
	=	0.22

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Arcadia Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Arcadia Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcadia Biosciences (Arcadia Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Arcadia Biosciences Inc (NAS:RKDA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

17D:Germany 17D:Germany

Address

5950 Sherry Lane, Suite 215, Dallas, TX, USA, 75225

Website

https://www.arcadiabio.com

Arcadia Biosciences Inc is a producer and marketer of innovative, plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements primarily in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care.

Executives

Thomas J. Schaefer	officer: Chief Financial Officer	202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Stanley Jr Jacot	officer: Chief Executive Officer	202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Pamela Haley	officer: Chief Financial Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Laura Pitlik	officer: Chief Marketing Officer	202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Chris Cuvelier	officer: Chief Growth Officer	202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Deborah D Carosella	director	3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025
Matthew T Plavan	officer: Chief Financial Officer	C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Randall Shultz	officer: Chief Technology Officer	4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018
Sarah Reiter	officer: Chief Commercial Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Lilian Shackelford Murray	director	228 BEACH ROAD, BELVEDERE CA 94920
Kevin Comcowich	director	C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
Eric J. Rey	director, officer: President and CEO	ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Zhongjin Lu	officer: VP Product Development	ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Amy Yoder	director	C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328